MOG

IgA: a new biomarker of demyelinating disease 5:04
IgA: a new biomarker of demyelinating disease
Anne-Katrin Pröbstel • 26 Apr 2023
MOG-IgA characterizes a subgroup of patients with central nervous system demyelination 4:40
MOG-IgA characterizes a subgroup of patients with central nervous system demyelination
Anne-Katrin Pröbstel • 26 Apr 2023
Demyelinating disorders: Impact of a novel biomarker on clinical practice 1:59
Demyelinating disorders: Impact of a novel biomarker on clinical practice
Anne-Katrin Pröbstel • 26 Apr 2023
Research developments in MOGAD 1:23
Research developments in MOGAD
Michael Levy • 25 Feb 2022
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD 1:32
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD
Michael Levy • 25 Feb 2022
Predictive and prognostic biomarkers for pediatric MOGAD and NMOSD 3:04
Predictive and prognostic biomarkers for pediatric MOGAD and NMOSD
Brenda Banwell • 26 Apr 2021
Update on pediatric NMOSD and MOGAD 3:47
Update on pediatric NMOSD and MOGAD
Brenda Banwell • 26 Apr 2021
Revising the neuromyelitis optica criteria 4:39
Revising the neuromyelitis optica criteria
Angela Vincent • 30 Oct 2020
The content of VJNeurology is intended for healthcare professionals